Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer
The purpose of this trial is to investigate the efficiency of pain relief and the safety of NPC-06 for the neuropathic pain associated with cancer, in addition to explore the effective concentration of NPC-06.
Neuropathic Pain in Cancer
DRUG: NPC-06
Improvement of Numeric Rating Scale (NRS) score within 2 hours after administration, Average change (slope) of NRS score, Pre-administration, 30, 60, 90 and 120 minutes post-administration
Other improvements of NRS score, Change of NRS score, Change of NRS score of persistent pain, Change of maximum pain, at the time of evaluation compared to baseline, Pre-dose, Days 1,2,3,4,5,6,7,8,9,10,11,12,13|Time to event, Time to event analysis of analgesic effect, 2 hours after initial administration to Day 7|Improvement of Neuropathic Pain Symptom Inventory (NPSI) score, Change of NPSI score compared to baseline, Pre-dose, Days 1,2,3,4,5,6,7,8,9,10,11,12,13|Rescue medication use, Number of times of rescue medication use, Day 1 to Day 13|Effective concentration, Blood phenytoin concentration, Day 0 to Day 13
The eligible patients will be randomized into three groups, and will receive NPC-06 (high dose), NPC-06 (low dose) or placebo once a day for 7 days.